Sheet __1_ of _6

FORM PTO-1449 U.S. DEPARTMENT OF COMME PATENT AND TRADEMARK OF					ATTY. DOCKET NO.: SERIAL NO.: TO BE ASSIGNED					
INFORMATION DISCLOSURE STATEMEN					APPLICANT:					
IINEC			LICANT	AT EIVIENT	WING-KEE PI	HILIP CH				
	(U.	se several she	ets if necess	ary)	FILING DATE: 11/03/2002	GROUP: 1615				
		_	U.S. P.	ATENT DOCU	MENTS					
XAMINER		DOCUMENT	DATE	NAM	1E	CLASS	SUB-	FILING		
/HS/		NUMBER					CLASS	APPRO	PRIAT	
/110/	AA	6,521,254 B2	02/18/2003	Weinstein, et al		424	468			
-		6,514,520 B2 6,506,767 B1	02/04/2003	Munayyer, et al Schumacher, et		424 514	439 290			
		6,132,758	10/17/2000	Munayyer, et al	31	424	439	ļ		
		6,100,274	08/08/2000	Kou		514	290			
$-\!$	AF	6,051,585	04/18/2000	Weinstein, et al	514	335	-			
-		5,939,426	08/17/1999	McCullough	514	290				
		5,900,421	05/04/1999	Handley, et al.		514	290	-		
_		5,731,319	03/24/1998	Aberg, et al.		514	290	-		
	AJ	5,595,997	03/24/1996	Aberg, et al.		514	290			
_		5,476,856	12/19/1995	Carceller, et al		514	290	-		
-		5,470,830	04/18/1995	Carceller, et al		514	290	-		
		5,314,697	05/24/1994	Kwan, et al.	-	424	480			
_		5,100,675	03/31/1992	Cho, et al.		424	468			
+		5,089,496				514	253	-		
-		5,019,591	05/28/1991	Gardner, et al.	514	461				
		4,990,535	02/05/1991	Cho, et al. Kouchiwa, et al		514	556			
_		4,990,555	03/06/1990			514	356			
		4,863,931	09/05/1989	Schumacher, et		514	290			
₩—	AT	6.270.796 B1	08/07/2001	Weinstein, et al	424	457				
/HS/				514	278	-				
,,,,,,,	170	4,004,000		PATENT DOC	LIMENTS	J 14	270			
	_	DOCUMENT	DATE	COUNTRY	OMENIO	CLASS	SUB-	TRANS	ATIC	
		NUMBER	DATE	COUNTRI		CLASS	CLASS	YES	NO	
/HS/	AV	0 264 259 A1	04/20/1988	European Patent	Office	A 61 K	31/44	IES	INO	
11107		0 288,640 A1	11/02/1988	European Patent		A61K	31/445		_	
+		0 396,404 A1	11/07/1990	European Patent		A61K	31/445	_	+	
+		0 396,404 B1	02/16/1994	European Paten		A61K	31/445	 	+	
1/	AZ	0 577 957 A1	01/12/1994		European Patent Office		401/00	 	-	
Ψ	BA	WO 85/03707	08/29/1985	WIPO	Omoo	C07D	701/00	t	\vdash	
/HS/		WO 92/00293	01/09/1992	WIPO			-		+	
				ling Author, Titl	e Date Pert	inent Pa	iges Et	c)		
	BC	Andersen et al	"Adverse drug	interactions clinic	ally important fo	or the der	matologis	t" Arch		
/HS/	-	Dermatol, April,			any important to	, uci	···acologic	, , Alon		
1101	BD	Babe, et al., "Hi	stamine. Brady	kinn, and their Ant	agonists" in The	Pharma	cological	Basis of	F	
/HS/		Therapeutics (9	(1996)	gioui	2200 0					
/HS/	BE	Barnett, et al.,"	harmacology o	f Non-Sedating H	Antihistamines	", New F	erspecti	ves in		
XAMINER	Ļ	nistamine Rese	earch, Birknaus	er Verlag Basel, pp		1).				
AAMINE	τ.	/Humera Sheik	h/	DATE	ONSIDERED	07/2	6/2007			
	D. 1-	itial if referen	oonsideredt	ether or not citation	1-1		MDED CO	O. D.	. Um -	

Sheet 2 of 6

FORM PTO-1449 U.S. DEPARTMENT OF COMM PATENT AND TRADEMARK O						ATTY. DOCKE PD01059KQ		SERIAL TO BE		IED
INFORMATION DISCLOSURE STATEMEN						APPLICANT:				
IINIC) (IVI	BY APPI		- I EIVIEI	• •	Wing-Kee P	hilip Cho			
(Use several sheets if necessary)						FILING DATE: GROUP: 11/03/2003 1615				
			U.S. P.	ATENT	DOCUN	/ENTS				
XAMINER		DOCUMENT	DATE		NAN	IE .	CLASS	SUB-	FILING	
INITIAL		NUMBER					1	CLASS	APPRO	PRIATE
/HS/	BF	4,783,465	11/08/1988	Sunshin			514	255		
			10/11/1988	Heinrich			514	226.2	ļ	
	ВН	4,731,447	03/15/1988	Schuma		al	546	93	ļ	
	ВІ	4,659,716	04/21/1987	Villani, e			514	290		
	BJ	4,552,899	11/12/1985	Sunshin			514	568		
	BK	4,371,516	02/01/1983	Gregory	, et al.		424	22		
	BL	4,282,233	08/04/1981	Vilani			424	267		
	ВМ	4,008,796	02/22/1977	Aylon			198	460		
7/7	BN	3,940,485	02/24/1976	Levinsor	n, et al.		424	250		
- V			11/04/1975		Theeuwes, et al.			260		
/HS/		3,845,770	11/05/1974	Theeuw			128 128	260		
			FOREIGN	IPATEN	IT DOC	LIMENTS				
		DOCUMENT	DATE	COUNTR		OWILITIO	CLASS	SUB-	TRANS	LATIO
		NUMBER	DATE	COOM			CEAGG	CLASS	YES	INO
/HS/	BQ	WO 92/11034	07/09/1992	WIPO				02.00		110
/HS/	BR	WO 92/20377	11/26/1992	WIPO				-	—	+
/HS/	BS	WO 96/20708	07/11/1996	WIPO			+	 		+
/HS/	BT	WO 96/16641	06/06/1996	WIPO			+	<u> </u>	-	+
/HS/	BU	WO 98/34614	08/13/1998	WIPO			+	<u> </u>	_	+
					T-11	5.4.5				1
	BV	HER DOCUME Berge, et al., "PI	NIS (Includ	ing Auti	or, IIII	e, Date, Per	tinent Pa	iges, El	C.)	1
/HS/	P	19.	iarmaceutical	Sails , J. C	or Phann.	. Sciences, Jai	luary, 197	7, VOI. 0	o, INO. I ,	pp. 1-
	BW	Berthon, et al., "	n Vitro inhibitio	on, by lora	tadine ai	nd descarboxy	ethoxylora	tadine. c	f histam	ine
/HS/		Berthon, et al., "In Vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3)", Biochem. Pharm., 1994, Vol. 47, No.5, pp. 789-794.								
/HS/	вх									
/110/		Sciences, November, 1972, Vol. 61, No.11, pp. 1770-1775.								
	BY									
/HS/		some H1-antihistamines: predictive in vitro correlates", J. of the National Cancer Inst., May 18,								
		1994, Vol. 86, N								
/HS/	BZ	Brandes, et al., relevant doses",						ant drug	s at clin	ically
XAMINE	_	relevant doses,	Caricer Resea	itch, July		ONSIDERED	30-3000.			
AMMINE	`	Alimana Ob -	lide/		DAILC	ONSIDEKED	V.	7/26/200	7	
/Humera Sheikh/							U	11201200	,	
		nitial if reference of								

33723

applicant.

/HS/

U.S. DEPARTMENT OF COMMERCE

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT

SERIAL NO ATTY, DOCKET NO .: PD01059KO TO BE ASSIGNED

GROUP:

1615

APPLICANT: Wing-Kee Philip Cho

FILING DATE

11/03/2003

BY APPLICANT (Use several sheets if necessary)

			U.S. PA	ATENT DOCUMENTS			
*EXAMINER		DOCUMENT	DATE	NAME	CLASS	SUB-	FILING DATE IF
INITIAL		NUMBER				CLASS	APPROPRIATE
/HS/	CA	3,598,123	08/10/1971	Zaffaroni	128	268	
/HS/	СВ	3,536,809	10/27/1970	Applezweig	424	28	
			FOREIGN	PATENT DOCUMENTS			

DATE COUNTRY

DOCUMENT CLASS SUB-TRANSLATION NUMBER CLASS YES NO /HS/ CC WO 00/2560 01/20/2000 PCT International

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) CD Brion, et al., "Evaluation of the antimuscarinic activity of atropine, terfenadine and meguitazine in

healthy volunteers", Br. J. Clin. Pharmac. 1988, Vol. 25, pp.27-32. Carmeliet, "Voltage- and Time-Dependent Block of the Delayed K+ Current in Cardiac Myocytes ĈĒ by Dofetilide", The J. of Pharm. And Experimental Therapeutics, 1992, Vol. 262, No. 2, pp. 809-817 Castello, et al., "Discoloration of tablets containing amines and lactose", J. of Pharm, Sciences.

February, 1962, Vol. 51, No.2, pp. 106-108. Cheung, et al., "Investigation of anti-motion sickness drugs in the squirrel monkev". J. Clin. Pharmacol, 1992, Vol. No. 32, pp. 163-175. Clissold, et al., "Loratadine: A preliminary review of its pharmacodynamic properties and

therapeutic efficacy", Drugs, 1989, Vol. 37, pp. 42-57. CI Cooke, "Glycopyrrolate in bladder dysfunction", SA Medical Journal, January 1,1983, p. 3. "Torsade de pointes after astemizole overdose", Br. Medical Journal, 1986,, Vol. 292, p. 660. Dorie, et al., "Antagonist Binding Profiles of Five Cloned Human Muscarinic Receptor Subtypes".

The J. of Pharm. And Experimental Therapeutics, 1991, Vol. 256, pp. 727-733. Drug Facts and Comparisons, 1998 Ed., Facts and Comparisons, St. Louis, Missouri, p. 2832. CM Ebert, "Soft elastic gelatin capsules: a unique dosage form", Pharmaceutical Technology, 1977, pp. 44-50.

Gengo, "Dilemma: Antihistamine selection: Use vs. Side effects", U.S. Pharmacist, November, 1990, pp. 59-92.

CO Hartauer, et al., A Comparison of Diffuse Reflectance FT-IR Spectroscopy and DSC in the Characterization of a Drug-Excipient Interaction, "Drug Development and industrial Pharmacy". 1991, Vol. 17, No. 4, pp. 617-630.

Herron, et al, "Dose Proportionality, Linearity, and Pharmacokiinetics of Desloratadine in Healthy Volunteers" (Abstract 1126), J. Allergy Clin. Immunol., January, 2000, Vol. 105, No. 1, Part 2, p. S385. Herzog, et al., "Urinary Incontinence: medical and Psychosocial Aspects", Annual Review of

Gerontology and Geriatrics, 1989, Vol. 9, pp. 74-119. CR Hilbert, et al., "Pharmacokinetics and Dose Proportionality of Loratadine", J. Clin. Pharmacol.

1987, Vol. 27, pp. 694-98. Housley, et al., "Histamine and related substances influence neurotransmission in the

semicircular canal", Hearing Research, May 1, 1988, Vol. 35, pp. 87-97. Jankowski, et al., "Effect of Terfenadine on Nnasal Provocation", Int. Arch. Allergy Immunolog.

1993, Vol. 101, pp. 311-317. Kaliner, "Nonsedating Antihistamines: Pharmacology, Clinical Efficacy and Adverse Effects", American Family Physician, March, 1992, Vol. 45, No. 3, pp. 1337-1342.

Kleine-Tebbe, et al., "Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine", J. Allergy Clin. Immunol., 1994, Vol. 93, pp. 494-500.

CW Knowles, "Astemizole and Terfenadine-Induced Cardiovascular Effects". The Canadian J. of /HS/ Hospital Pharmacy, February, 1992, Vol. 45, No. 1, pp. 33 & 37. EXAMINER

/Humera Sheikh/

07/26/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citational not interestinates and considered bloods xoc to this form with next communication to applicant

Sheet 4 of 6 FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO .: SERIAL NO: PATENT AND TRADEMARK OFFICE PD01059KQ TO BE ASSIGNED INFORMATION DISCLOSURE STATEMENT APPLICANT: Wina-Kee Philip Cho BY APPLICANT FILING DATE: GROUP: (Use several sheets if necessary) 11/03/2003 1615 U.S. PATENT DOCUMENTS EXAMINER DOCUMENT DATE NAME CLASS SUB-FILING DATE IF INITIAL NUMBER CLASS APPROPRIATE FOREIGN PATENT DOCUMENTS DOCUMENT DATE COLINTRY CLASS SUB. TRANSLATION NUMBER CLASS YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) /HS/ Kohl, et al., "Lack of Effects of Astemizole on Vestibular Ocular Reflex, Motion Sickness, and Cognitive Performance in Man", Aviation, Space, and Environmental Medicine, December, 1987, pp. 1171-1174. Kohl, et al., "New Pharmacologic Approaches to the Prevention of Space/Motion Sickness", J. Clin. Pharmacol., 1991, Vol. 31, pp. 934-946. CZ Kohl., et al., "Control of Nausea and autonomic dysfunction with terfenadine, a peripherally acting antihistamine", Aviation, Space and Environmental Medicine, May, 1991, pp. 392-396. DA Kreutner, et al, "Profile of Desloratadine as a Selective and Non-Sedating Histamine H1-Receptor Antagonist", Preclinical Efficacy and Antiallergic, J. Allergy Clin. Immunol. (Abstract 1118), Vol. 105, No. 1, part 2, pp. S382-383. Kubo, et al., "Antimuscarinic Effects of Antihistamines: Quantitative Evaluation by Receptor-Binding Assay", Japan J. Pharmacol., 1987, Vol. 43, pp. 277-282. Lathers, et al., "Pharmacology in space: Part 2. Controlling motion sickness", TiPS, June, 1989, Vol. 10. pp. 243-250. DD Levin, et al., "Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder", The J. of Urology, August, 1982, Vol. 128. pp. DE Lunde, "Antihistamines", Side Effects of Drugs Annual 14, Elsevier Science Publishers B.V., 1990, pp. Lunde, "Antihistamines", Side Effects of Drugs Annual 12; A Worldwide Yearly Survey of New Data and Trends, Elsevier Science Publishers B.V., 1998, pp. 142-143. DG Massad, et al., "The Pharmacokinetics of Intravesical and Oral Oxybutynin Chloride", The J. of Urology, August, 1992, Vol. 148, pp. 595-597. McCue, "Safety of Antihistamines in the Treatment of Allergic Rhinitis in Elderly Patients", Arch. Fam. Med., September, 1996, Vol. 5, pp. 464-468. Miadonna, et al., "Inhibitory Effect of the H1 Antagonist Loratadine on Histamine Release from Human ū Basophils", Int. Arch. Allergy Immunol., 1994, Vol. 105, pp. 12-17. Mirakhur, et al., "Glycopyrrolate: Pharmacology and Clinical Use", Anaesthesia, 1983, Vol. 38, pp. 1195-DK Mitchelson, "Pharmacological Agents Affecting Emesis: A Review (Part II)", Drugs, 1992, Vol. 43, No. 4,

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 33725

pp. 443-463.

Vol. 156, pp. 1989-1990.

/Humera Sheikh/

/HS/ DI

EXAMINER

Muskat, et al., "The Use of Scopolamine in the Treatment of Detrusor Instability", The J. of Urology, 1996.

DATE CONSIDERED

07/26/2007

Sheet 5 of 6 FORM PTO-1449 ILS DEPARTMENT OF COMMERCE ATTY DOCKET NO . SERIAL NO : PATENT AND TRADEMARK OFFICE PD01059KQ TO BE ASSIGNED APPLICANT: INFORMATION DISCLOSURE STATEMENT Wing-Kee Philip Cho BY APPLICANT FILING DATE: GROUP: (Use several sheets if necessary) 11/03/2003 1615 U.S. PATENT DOCUMENTS. *EXAMINER DATE NAME DOCUMENT CLASS FILING DATE IF SUB-CLASS APPROPRIATE INITIAL NUMBER FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY CLASS SUB-TRANSLATION NUMBER CLASS YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Nelemans, "Antiallergic and antitussive drugs", Side Effects of Drugs Annual 12, Elsevier Science /HS/ Publishers B.V., 1988, pp. 144-147. DИ Nomeir, et al., "Influence of Food on the Oral Bioavailability of Loratadine and Pseudoephedrine from Extended-Release Tablets in Healthy Volunteers", J. Clin. Pharm, 1996, Vol. 36, No. 10, pp. 923-930. Padhi, et al., "Multiple-Dose Pharmacokinetics; Safety and Tolerance of Desloratadine in Healthy Volunteers (Abstract 1124), January, 2000, J. Allergy Clin. Immunol., January, 2000, Vol. 105, No. 1, part 2, p. S385. DP Parkinson, et al., "Evaluation of Loratadine as an Inducer of Liver Microsomal Cytochrome P450 in Rats and Mice", Biochemical Pharmacology, 1992, Vol. 43, No. 10, pp. 2169-2180. DQ Peggs, et al., "Antihistamines: The Old and the New", American Family Physician. August, 1995, Vol. 52, No. 2, pp. 593-600. DR Petrin, "Bewegungskrankheit und ihre Therapie/ Eine Übersicht (Motion Sickness and its Treatment)". Schweiz, Rundschau Med., 1974, (PRAXIS) 63, pp. 79-81. DS Ouercia, et al., "Focus on Loratadine: A new second-generation nonsedating H1-receptor antagonist". Hosp. Formul., February 1993, Vol. 28, pp. 137, 138, 141, 142, 144, 149, & 153. Remington's Pharmaceutical Sciences, 18th Ed. Alfonso R. Gennaro, Mack Publishing Company, Easton, PA, 1990, pp. 1519-1520. Remington's Pharmaceutical Sciences, 18th Ed. Alfonso R. Gennaro, Mack Publishing Company, Easton, PA, 1990, pp. 1527-1529 DV Resnick, "Urinary incontinence", The Lancet, July 8, 1995, Vol. 346, pp. 94-99. Roman, et al., "Loratadine-A Review of Recent Finding in Pharmacology Pharmacokinetics, Efficacy, and Safety, with a Look at its Use in Combination with Pseudoephedrine", Clin. Reviews in Allergy, 1993. Vol. 11, pp. 89-110. DX Salmun, et al., "Efficacy and Safety of Desloratadine in Seasonal Allergic Rhinitis, January, 2000, J. Allergy Clin. Immunol. (Abstract 1123), Vol. 105, No. 1, Part 2, pp. S384-385. Simons, "H1-Receptor Antagonists Comparative Tolerability and Safety", Drug Safety, 1994, Vol. 10, No. 5, pp. 350-380 Sunahara, et al., "Pharmacological interventions for motion sickness: Cardiovascular Effects", Aviation, Space and Environmental Medicine, September, 1987, pp. A270-A276. Temple, et al., "Loratadine, an Antihistamine, Blocks Antigen-and Ionophore-Induced Leukotriene Release from Human Lung In Vitro", Prostaglandins, 4/1988, 35(4):549-554. FR Van Cauwenberge, "New Data on the Safety of Loratadine", Drug Invest., 1992, Vol. 4, No. 4, pp.283-291. Van Peer, et al. "Ketoconazole Inhibits Loratadine Metabolism in Man", Beerse, Belgium, Abstract 1234,

p. 34. EXAMINER /Humera Sheikh/

FD

/HS/

DATE CONSIDERED 07/26/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Wade, et al., Handbook of Pharmaceutical Excipients (2nd edition), American Pharmaceutical Association and Pharma Press, Royal Pharma. Society of G. Britain, 1994, pp. 257&259.

Sheet 6 of 6

FORM PTO	1449	IIS DEF	ARTMENT	OF COMMERC	F	ATTY, DOCKE	L NO .	SERIAL	NO ·		
PATENT AND TRADEMARK OF						PD01059KQ TO BE ASSIGNED					
INFORMATION DISCLOSURE STATEMEN						APPLICANT:					
		BY APPLIC	ANT			Wing-Kee Pt	nilip Cho				
(Use several sheets if necessary)						FILING DATE: GROUP: 11/03/2003 1615					
			U.S. P	ATENT DO	CUA	/FNTS					
*EXAMINER	Г	DOCUMENT DATE			NAME					LING DATE IF	
INITIAL		NUMBER						CLASS	APPROPRIATE		
	<u> </u>						191				
	-		<u> </u>								
	\vdash										
			OREIGN	PATENT D	ОС	UMENTS					
		DOCUMENT	DATE	COUNTRY			CLASS	SUB-	TRANSLATION		
		NUMBER						CLASS	YES	NO	
	1									\vdash	
		-	ļ					-		\vdash	
	-							ļ		\vdash	
										\vdash	
	ОТ	HER DOCUMEN	S (Includ	lina Author.	Title	e. Date. Pert	inent Pa	aes. Et	C.)		
/HS/	ĒĒ.	HER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Wein, "Pharmacology of Incontinence", Urologic Clinics of North America, August, 1995, Vol. 22, No. 3,									
/H5/		pp. 557-577.									
/HS/	EF	Wirth, et al., Mailland					de, a Seco	ndary Am	ine, Jour	nal of	
/HS/	EG	Pharmaceutical Sciences, Jan. 1998, Vol. 87, No.1, pp.31-39.									
	EH	Wood, "Antimotion Sickness and Antiemetic Drugs", Drugs, 1979, Vol.17, pp. 471-479. Wood, et al., "Mechanisms of Antimotion Sickness Drugs", Aviation, Space, and Environmental Medicine,									
/HS/		September 1987, pp. A262-A265.									
/HS/	El	The United States Pha		The United Stat	es Fo	rmulary, United	States Pha	ттасореі	al Conve	ntion,	
/110/		Inc., Rockville, MD.									
/HS/	EJ	Yarker, et al., "Oxybutynin, A Review of its Pharmacodynamic and Pharmacokinetic Properties, and its									
	EK	Therapeutic Use in Detrusor Instability", Drugs and Aging, 1995, Vol. 6, No. 3, pp. 243-262 Zhong, et al., "HPLC-Determination of Loratadine and its active metabolite descarboethoxyloratadine in									
/HS/	-	Zhong, et al., "HPLC-Determination of Loratadine and its active metabolite descarboethoxyloratadine in human plasma", Pharmazie, 1994, Vol. 49(H. 10), pp. 736-739.									
		numum pluomia , r man	IMLIC, 1771,	101. 17(11. 10)	, pp.	750 755.					
EXAMINE	R			DA1	TE C	ONSIDERED					
		/Humera Sheikh/			07/26/2007						
*EV AMINI	7D. L	nitial if reference consid					SAL MOTED	600. D-	me lim a Ale	-auah	
		onformance and not co								iougn	